GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anthem Biosciences Ltd

Anthem Biosciences Q1 FY27 Consolidated Net Profit ₹1,199 Mn, Down 11.7% YoY

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 04:52 PM IST  ·  BSE ID: 20786a3b-e4a8-40e1-aa55-32d4f93c101d
View Original BSE Filing (PDF)
💡
In Simple Terms
Anthem Biosciences' quarterly profit and revenue decreased, but its cash holdings increased and profit margins improved.
🤖 AI Summary
  • Anthem Biosciences' Q1 FY27 consolidated Profit After Tax (PAT) decreased 11.7% YoY to ₹1,199 Mn.
  • Revenue from Operations for Q1 FY27 was ₹4,182 Mn, a 22.6% decline from ₹5,402 Mn in Q1 FY26.
  • EBITDA stood at ₹1,755 Mn in Q1 FY27, with EBITDA margins at 39.6%, up from 38.1% in Q1 FY26.
  • Net Cash position as of June 30, 2026, was ₹17,197 Mn, an increase from ₹7,848 Mn as of June 30, 2025.
  • CRDMO segment revenue was ₹3,408 Mn, while Specialty Ingredients contributed ₹774 Mn to Q1 FY27 revenues.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit after tax (Q1FY27)
₹1,199 Mn
-11.7%
Revenue from Operations (Q1FY27)
₹4,182 Mn
-22.6%
EBITDA (Q1FY27)
₹1,755 Mn
-18.1%
EBITDA Margins (Q1FY27)
39.6%
153 bps
Net Cash (June 30, 2026)
₹17,197 Mn
🏢 How This Affects the Company
📈
Business Impact
Consolidated Revenue from Operations declined by 22.6% YoY, driven by reductions in both CRDMO and Specialty Ingredients segments, reflecting shifts in customer delivery schedules.
💰
Financial Impact
Profit After Tax decreased by 11.7% YoY to ₹1,199 Mn. However, EBITDA margins improved to 39.6% from 38.1% in Q1 FY26, and the company's Net Cash position increased to ₹17,197 Mn.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results presentation.
👤
Who Is Affected
Shareholders are affected by the company's Q1 FY27 financial performance, which includes a decrease in Profit After Tax to ₹1,199 Mn and reduced revenue.
🔍
Management Signal
Management indicates commitment to sustaining revenue growth aligned with long-term historical performance and maintaining industry-leading margin profile through cost efficiencies.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate if revenue recovery aligns with management's commentary.
CRDMO and Specialty Ingredients segment performance — track growth in key business areas.
EBITDA and PAT margins — monitor continued improvement and stability in profitability.
MEDIUM RISK Significant YoY revenue and profit decline presents a near-term business risk, despite management's positive outlook for later quarters.
💡 Investor Takeaway
Anthem Biosciences reported Q1 FY27 consolidated Profit After Tax of ₹1,199 Mn, down 11.7% YoY, on a 22.6% decline in Revenue from Operations to ₹4,182 Mn. EBITDA margins improved to 39.6%, and Net Cash grew to ₹17,197 Mn. Management signals strong underlying demand for later in the year.
⚖️ Strengths & Concerns

✅ Positives

  • EBITDA margins for Q1 FY27 improved to 39.6% from 38.1% in Q1 FY26, indicating disciplined cost efficiencies and yield optimisation.
  • Net Cash position significantly increased to ₹17,197 Mn as of June 30, 2026, from ₹7,848 Mn as of June 30, 2025.

⚠️ Concerns

  • Revenue from Operations for Q1 FY27 decreased 22.6% YoY to ₹4,182 Mn, impacting the top-line performance.
  • Profit After Tax for Q1 FY27 declined by 11.7% YoY to ₹1,199 Mn from ₹1,358 Mn in Q1 FY26.
📅 Company Track Record
Anthem Biosciences' Q1 FY27 net profit of ₹1,199 Mn represents a decline from the ₹1,358 Mn reported in Q1 FY26. Past filings context for Q1 FY27 had already indicated a net profit decrease of 11.7% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Anthem Biosciences' consolidated net profit in Q1 FY27?
Anthem Biosciences reported a consolidated Profit After Tax of ₹1,199 Mn for Q1 FY27.
How much did Anthem Biosciences' revenue from operations decline in Q1 FY27?
Revenue from Operations for Anthem Biosciences in Q1 FY27 decreased by 22.6% to ₹4,182 Mn compared to Q1 FY26.
What was Anthem Biosciences' EBITDA margin in Q1 FY27?
Anthem Biosciences' EBITDA margin for Q1 FY27 was 39.6%, an improvement of 153 bps from 38.1% in Q1 FY26.
What was Anthem Biosciences' Net Cash position as of June 30, 2026?
As of June 30, 2026, Anthem Biosciences maintained a Net Cash position of ₹17,197 Mn.
What were the revenues for Anthem Biosciences' CRDMO and Specialty Ingredients segments in Q1 FY27?
For Q1 FY27, CRDMO business delivered ₹3,408 Mn in revenues, and Specialty Ingredients delivered ₹774 Mn.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.